未找到相关数据
A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma
被引：0
|作者：
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Khadar, Kattie
Trepel, Jane B.
Schlom, Jeffrey
Arlen, Philip M.
Merino, Maria
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Kurdziel, Karen A.
Folio, Les
Figg, William Douglas
Agarwal, Piyush K.
Bottaro, Donald P.
Dahut, William L.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[6] NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA
[7] NCI, NIH, Bethesda, MD 20892 USA
[8] NCI, Biostat & Data Management Sect, CCR, Bethesda, MD 20892 USA
[9] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] NCI, Mol Imaging Program, CCR, NIH, Bethesda, MD 20892 USA
[11] NIH, Bethesda, MD 20892 USA
[12] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[13] NCI, Urol Oncol Branchd, NIH, Bethesda, MD 20892 USA
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4589
引用
收藏
页数：2
相关论文